Fig. 3

CCNE1 amplification, but not MYC amplification, was associated with the overall survival of GCLM patients. A–D The Kaplan–Meier curves of PFS (A, C) or OS (B, D) in GCLM patients stratified by CCNE1 amplification status that was assessed by tumor tissue samples (A, B) or CSF (C, D). E–H The Kaplan–Meier curves of PFS (E, G) or OS (F, H) in GCLM patients stratified by MYC amplification status that was assessed by tumor tissue samples (E, F) or CSF (G, H). PFS, progression-free survival; OS, overall survival